18889881171
Kalkine 0
countryflagUS

Biodesix Inc

Healthcare US BDSX

0.2608USD
0.04(18.55%)

Last update at 2025-05-16T16:59:00Z

Day Range

0.220.30
LowHigh

52 Week Range

1.112.21
LowHigh

Fundamentals

  • Previous Close 0.22
  • Market Cap197.84M
  • Volume12938779
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-29.25900M
  • Revenue TTM65.56M
  • Revenue Per Share TTM0.57
  • Gross Profit TTM 24.06M
  • Diluted EPS TTM-0.37

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -65.44700M -43.15900M -31.35000M -30.72600M -26.16600M
Minority interest - - - - -
Net income -80.38800M -44.48000M -36.47300M -31.35500M -26.16600M
Selling general administrative 61.46M 50.52M 34.86M 30.64M 25.90M
Selling and marketing expenses 61.46M 50.52M 34.86M 30.64M 25.90M
Gross profit 24.06M 23.99M 23.56M 18.48M 16.03M
Reconciled depreciation 5.84M 3.18M 2.90M 2.79M 1.74M
Ebit -50.50600M -39.31800M -22.11600M -22.62700M -19.27200M
Ebitda -50.39700M -39.32700M -21.67600M -22.15800M -17.53200M
Depreciation and amortization 0.11M -0.00900M 0.44M 0.47M 1.74M
Non operating income net other - - - - -
Operating income -50.50600M -39.31800M -22.11600M -22.62700M -23.46100M
Other operating expenses 88.72M 93.82M 67.67M 47.18M 38.49M
Interest expense 8.07M 4.51M 7.60M 3.01M 2.92M
Tax provision - - - - -
Interest income - - 0.02M 0.06M 0.02M
Net interest income -8.07200M -4.50800M -7.58600M -2.95300M -2.89200M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 14.94M 1.32M 5.12M 0.63M 0.21M
Total revenue 38.21M 54.51M 45.56M 24.55M 20.43M
Total operating expenses 74.56M 63.31M 45.67M 41.10M 34.09M
Cost of revenue 14.15M 30.52M 22.00M 6.07M 4.41M
Total other income expense net -14.94100M -3.84100M -9.23400M -8.09900M -5.21300M
Discontinued operations - - - - -
Net income from continuing ops -65.44700M -43.15900M -31.35000M -30.72600M -26.16600M
Net income applicable to common shares -65.44700M -43.15900M -31.35000M -30.72600M -26.16600M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 99.10M 92.91M 76.10M 121.07M 41.63M
Intangible assets 7.91M 9.80M 11.62M 13.26M 15.09M
Earning assets - - - - -
Other current assets 4.22M 5.18M 7.25M 8.71M 2.12M
Total liab 94.52M 72.30M 56.37M 79.90M 270.17M
Total stockholder equity 4.58M 20.61M 19.73M 41.17M -228.53900M
Deferred long term liab - 0.65M - - -
Other current liab 29.86M 18.60M 25.43M 7.79M 7.44M
Common stock 0.10M 0.08M 0.03M 0.03M 0.00100M
Capital stock 0.10M 0.08M 0.03M 0.03M 0.00100M
Retained earnings -419.56600M -367.42000M -301.97300M -258.81400M -230.86400M
Other liab - 19.20M 17.42M 31.85M 29.80M
Good will 15.03M 15.03M 15.03M 15.03M 11.63M
Other assets - 5.92M 1.66M 3.46M 0.09M
Cash 26.38M 43.09M 32.71M 62.13M 5.29M
Cash and equivalents - - - - -
Total current liabilities 33.42M 22.84M 28.96M 32.12M 22.60M
Current deferred revenue 0.32M 0.96M 1.85M 3.53M 1.28M
Net debt 34.31M -11.23800M -22.70000M -34.36000M 30.68M
Short term debt 0.30M 1.59M 0.02M 11.84M 12.16M
Short long term debt 0.05M 0.05M 0.02M 11.84M 12.16M
Short long term debt total 60.69M 31.85M 10.01M 27.77M 35.97M
Other stockholder equity 424.05M 387.95M 321.67M 299.95M 2.32M
Property plant equipment - 8.82M 4.18M 3.18M 2.12M
Total current assets 39.68M 53.33M 43.61M 86.14M 12.70M
Long term investments - - - - -
Net tangible assets - -4.22200M -6.92100M 12.88M -255.26200M
Short term investments - - - - -
Net receivables 7.68M 5.07M 3.66M 15.30M 5.29M
Long term debt 35.23M 25.00M 9.99M 15.93M 23.81M
Inventory 1.40M 1.40M 2.90M 3.20M 0.80M
Accounts payable 2.93M 1.69M 1.66M 8.96M 1.72M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.00000M - - -121.07000M -6.38600M
Additional paid in capital - - - - -
Common stock total equity - - - 0.03M 0.00100M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 6.86M 5.92M 1.66M 3.46M 0.09M
Deferred long term asset charges - - - - -
Non current assets total 59.41M 39.57M 32.48M 34.93M 28.93M
Capital lease obligations 25.41M 6.80M - - -
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -3.53400M -2.54700M -2.92700M -1.87200M -0.61700M
Change to liabilities -1.98600M -9.10700M 13.90M 1.98M 0.79M
Total cashflows from investing activities -3.53400M -2.54700M -2.92700M -1.87200M -0.61700M
Net borrowings 16.50M -15.51400M 16.04M 13.04M 10.77M
Total cash from financing activities 58.88M 1.26M 81.13M 22.97M 19.03M
Change to operating activities -0.85700M 2.24M -8.39600M 0.02M -0.38900M
Net income -65.44700M -43.15900M -31.35000M -30.72600M -26.16600M
Change in cash 10.38M -29.50800M 56.84M -0.62600M 0.74M
Begin period cash flow 32.80M 62.31M 5.47M 6.09M 5.36M
End period cash flow 43.17M 32.80M 62.31M 5.47M 6.09M
Total cash from operating activities -44.97200M -28.22300M -21.36600M -21.72600M -17.67700M
Issuance of capital stock 59.54M 16.67M 72.00M 10.00M 8.50M
Depreciation 5.84M 3.18M 2.90M 2.79M 1.74M
Other cashflows from investing activities - - - - -
Dividends paid - -0.32800M - - -
Change to inventory 0.91M 7.42M -11.65400M 0.02M -0.38900M
Change to account receivables -1.50100M 11.45M -10.30800M -3.64600M -0.14600M
Sale purchase of stock 0.35M 0.33M - - -
Other cashflows from financing activities 27.59M 30.02M 9.13M 22.97M 41.55M
Change to netincome 18.98M 7.17M 7.35M 7.45M 6.39M
Capital expenditures 3.53M 2.55M 2.18M 1.42M 0.62M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -4.34400M 4.59M -4.80100M -1.64500M 0.25M
Stock based compensation 5.96M 4.94M 3.71M 0.17M 0.14M
Other non cash items 13.01M 4.33M 6.58M 5.32M 6.31M
Free cash flow -48.50600M -30.77000M -23.54300M -23.14200M -18.29400M

Peer Comparison

Sector: Healthcare Industry: Diagnostics & Research

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
BDSX
Biodesix Inc		 0.04 18.55% 0.26 - - 3.02 7.05 3.46 -2.7189
TMO
Thermo Fisher Scientific Inc		 3.90 0.96% 408.83 34.71 23.87 4.62 4.43 5.29 20.89
DHR
Danaher Corporation		 3.54 1.86% 194.50 29.09 28.01 5.67 3.20 6.00 19.09
A
Agilent Technologies Inc		 0.88 0.78% 113.28 34.36 26.39 6.59 7.14 6.78 23.56
IDXX
IDEXX Laboratories Inc		 3.88 0.76% 515.87 49.99 45.66 11.29 27.85 11.46 34.46

Reports Covered

Stock Research & News

View All

Profile

Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR and NGS, and VeriStrat tests, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to establish the patient's prognosis and help guide treatment decisions. In addition, the company, through its partnership with Bio-Rad Laboratories, Inc., provides Bio-Rad SARS-CoV-2 ddPCR, a COVID-19 Test under Biodesix WorkSafe testing program; and Platelia SARS-CoV-2 Total Ab test, an antibody test for detecting a B-cell immune response to SARS-CoV-2 that indicate recent or prior infection. Further, it offers diagnostic and clinical research, as well as clinical trial testing services to biopharmaceutical companies; and discovers, develops, and commercializes companion diagnostics. The company was formerly known as Elston Technologies, Inc. and as changed to Biodesix, Inc. in 2006. Biodesix, Inc. was incorporated in 2005 and is headquartered in Louisville, Colorado.

Biodesix Inc

919 West Dillon Road, Louisville, CO, United States, 80027

Key Executives

Name Title Year Born
Mr. Scott Hutton Pres, CEO & Director 1972
Ms. Robin Harper Cowie CFO, Sec. & Treasurer 1980
Mr. Ryan H. Siurek Chief Accounting Officer 1972
Dr. Heinrich Röder Founder & CTO NA
Dr. Robert W. Georgantas III, Ph.D. Chief Scientific Officer 1971
Mr. Jeffrey A. Bojar VP of Legal and Regulatory Affairs NA
Mr. Matt Stauffer VP of Sales NA
Dr. Paul J. Beresford Chief Bus. Officer NA
Dr. Gary Anthony Pestano Ph.D. Chief Devel. Officer 1967
Ms. Bobbi Coffin Chief Growth Officer NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.